Register
Login:
Share:
Email Facebook Twitter

Share Views: The Cyber Security opportunity - What you need to know. Watch here

Share Views: The Cyber Security opportunity.
What you need to know.


Immupharma Share Chat (IMM)



Share Price: 36.00Bid: 36.00Ask: 37.50Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.50Spread as %: 4.17%Open: 36.50High: 36.50Low: 35.00Yesterday’s Close: 36.00


Share Discussion for Immupharma


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Lostinfrance
Posts: 14
Off Topic
Opinion:No Opinion
Price:36.00
RE: Lostinfrance
Fri 19:20
Yes they did and also took part of fees in shares too i think,
Yes lets hope we are in the 20% but the main thing is good results,
 
boomorbust
Posts: 8,186
Off Topic
Opinion:No Opinion
Price:36.00
RE: Lostinfrance
Fri 19:05
Yes - doesn't seem too unreasonable.

It's all in the hands of the CRO, Simbec-Orion now. Simbec-Orion only formed in 2014 and is trying to build its reputation as a boutique, full service CRO. As far as I know, it has picked up two phase III trials since it was launched, one in cancer with a French pharma. and the Lupuzor trial. These trials will be high profile for Simbec. They'll want to perform as well as they possibly can and that will include meeting recruitment targets. I believe they also took part in the recent fundraising so have a slice of the pie too.

Having said all of that, I seem to remember reading somewhere that around 80% of clinical trials miss recruitment targets. Let's hope we're in the 20% - time will tell!!
Lostinfrance
Posts: 14
Off Topic
Opinion:No Opinion
Price:36.00
RE: Lostinfrance
Fri 17:23
Thankyou for clarifying that,
So with 24 centres now recruiting? Approx 8 patients per centre,
And i would assume the american sites would find it easy to get a higher number than this,
If the sites all specialise in lupus, in my opinion i cant see why we will not have the recruitment in place this year,
boomorbust
Posts: 8,186
Off Topic
Opinion:No Opinion
Price:36.00
Lostinfrance
Fri 17:06
200 patients in total, randomly assigned to receive either Lupuzor or a placebo (plus standard of care treatment). So in effect roughly 100 should be allocated to the treatment arm and 100 to the control arm.
Lostinfrance
Posts: 14
Off Topic
Opinion:No Opinion
Price:35.00
200 patients
Fri 16:39
Just a question, may seem stupid, but is the trial 200 patients on lupuzor, ?
As half the trial is on placebo.

We had the same share drift the other week on no volume, then the massive buying which brought us back to the same price,
joily123
Posts: 189
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:35.00
RE: shaky
Fri 12:10
Strange after the massive buying volume just recently that this is going the other way.
Thebusdriver
Posts: 30
Off Topic
Opinion:No Opinion
Price:37.50
shaky
Fri 09:01
Bit shaky yesterday/today - on little volume. MM's working big sell in background?
hunkymonkey
Posts: 2,169
Off Topic
Opinion:No Opinion
Price:37.50
RE: Hunky
Fri 08:52
To be honest I'm a little surprised that they are not reporting the progress of patient recruitment - on one hand you can say what does it matter? However with the lanstead deal the higher the sp the more remuneration they receive. Do you know if that is capped after way, say 10% more of less?

With the non-movement of the sp in recent weeks, do you think lanstead are selling? We've consolidated 30s now, and with so few shares in free float, coupled with limited selling from pi. I was wondering where mm were getting shares from.
boomorbust
Posts: 8,186
Off Topic
Opinion:No Opinion
Price:37.50
RE: Hunky
Fri 08:22
Thanks.

From memory interims next month - will be interesting to see how they handle any update on Lupuzor, especially with regards to any preclinical progress in other diseases.
hunkymonkey
Posts: 2,169
Off Topic
Opinion:No Opinion
Price:37.50
RE: Hunky
Fri 08:12
The key milestones outstanding for this year is recruiting the full 200 patients into the trial

The further key milestone next year, end 2017, is reporting top line data

This was the response




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.